Remicade blunts serological response in SARS-CoV-2

Remicade use in inflammatory bowel disease was linked to attenuated serological response to SARs-CoV-2, which were further blunted by immunomodulators used as concomitant therapy, according to a study published in Gut.“Impaired serological responses to SARS-CoV-2 infection might have important implications for global public health policy and individual anti-TNF–treated patients,” Nicholas A. Kennedy, MBBS, FRACP, from the department of gastroenterology at University College London Hospitals, NHS Foundation Trust in London, United Kingdom, and colleagues wrote. “SerologicalRead More

Share on facebook
Share on twitter
Share on linkedin